Meta-Analysis
Copyright ©The Author(s) 2017.
World J Gastroenterol. Feb 28, 2017; 23(8): 1497-1506
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1497
Table 1 Main characteristics of the cross-sectional studies included in this meta-analysis
StudyCountryYearStudy sampleH. pylori testingH. pylori prevalence (%)ORStudy quality
Offerhaus et al[36]The Netherland1989DialysisAntibody22/50 (44%)0.96 (0.42-2.22)S 3
C 0
O 2
Shousha et al[55]United Kingdom1990DialysisHistology12/50 (24%)0.43 (0.20-0.90)S 3
C 0
O 2
Loffeld et al[34]The Netherland1991HDAntibody13/30 (43%)1.24 (0.58-2.64)S 3
C 1
O 2
Davenport et al[22]United Kingdom1991HDAntibody27/76 (36%)1.29 (0.75-2.22)S 3
C 1
O 2
Ala-Kaila et al[16]Finland1991HDHistology3/23 (13%)0.68 (0.17-2.64)S 3
C 0
O 2
Gladziwa et al[27]Germany1993HDCumulative evaluation (urease, test, histology, culture and direct examiniation)12/35 (34%)0.44 (0.19 -1.00)S 3
C 0
O 2
Giachino et al[25]Italy1994HDUrease test, histology and culture13/40 (32%)0.51 (0.20-1.28)S 3
C 0
O 2
De Vecchi et al[51]Italy1995HD and PDAntibodyHD and PDHD and PDS 3
37/67 (55%)0.39 (0.18-0.81)C 1
HDHDO 2
17/29 (59%)0.54 (0.18-1.62)
PDPD
20/38 (53%)0.30 (0.11-0.81)
Jaspersen et al[31]Germany1995HDUrease test and histology7/34 (21%)0.44 (0.18-1.09)S 3
C 0
O 2
Seyrek et al[39]Turkey1996HDAntibody13/91 (14%)0.56 (0.21-1.50)S 3
C 1
O 2
Krawczyk et al[33]Poland1996HDUrease test and histology13/21 (62%)0.93 (0.27-3.20)S 3
C 1
O 2
Ozgür et al[38]Turkey1997HDUrease test28/47 (60%)0.83 (0.41-1.69)S 3
C 0
O 2
Hruby et al[30]Poland1997HDAntibody, culture9/26 (35%) by culture0.68 (0.19-2.44) by cultureS 3
16/26 (62%) by antibody0.53 (0.13-2.12)C 0
O 2
Yildiz et al[42]Turkey1999HDAntibody31/47 (66%)0.79 (0.34-1.84)S 3
C 0
O 2
Fabrizi et al[23]United States1999HDAntibody127/228 (56%)1.11 (0.74-1.66)S 3
C 1
O 2
Tamura et al[40]Japan1999HD and PDUrease test, histology, and culture25/49 (51%)0.88 (0.40-1.96)S 3
C 0
O 2
Gür et al[28]Turkey1999HDUrease test and histology25/45 (56%)1.04 (0.45-2.40)S 3
C 0
O 2
Araki et al[50]Japan1999HD and PDHistology and culture29/63 (46%)0.45 (0.22-0.91)S 3
C 1
O 2
Karari et al[32]Kenya2000CRFUrease test and histology41/77 (53%)0.90 (0.48-1.70)S 3
(HD - 36%)C 1
O 2
Nakajima et al[53]Japan2002HDUrease test, histology, and culture14/51 (28%)0.30 (0.11-0.81)S 3
C 0
O 2
Tsukada et al[41]Japan2003HDHistology9/36 (25%)0.28 (0.02-3.82)S 3
C 2
O 2
Olmos et al[37]Argentina2003HDAntibody44/93 (47%)0.62 (0.35-1.11)S 3
C 2
O 2
Nakajima et al[54]Japan2004HDAntibody51/138 (37%)0.35 (0.22-0.58)S 3
C 1
O 2
Nardone et al[35]Italy2005HDUrease test, histology, urea breath test and stool antigen7/11 (64%)3.04 (0.82-11.13)S 3
C 0
O 2
Blusiewicz et al[19]Poland2005HDUrease, histology19/30 (63%)0.71 (0.24-2.07)S 3
C 0
O 2
Khedmat et al[13]Iran2007HDUrease test46/73 (63%)3.20 (1.88-5.44)S 3
C 0
O 2
Khazaei et al[52]Iran2008HD - childrenUrease test, and histology16/24 (67%)8.00 (2.19-29.25)S 3
C 0
O 2
Gioè et al[26]Italy2008HDUrease test, and histology75/142 (53%)1.39 (0.86-2.23)S 3
C 0
O 2
Abdulrahman et al[49]Saudi Arabia2008ESRDHistology16/40 (40%)0.22 (0.09-0.56)S 3
C 1
O 2
Asl et al[12]Iran2009HDHistology23/40 (58%)2.81 (1.13-6.99)S 3
C 1
O 2
Sugimoto et al[56]Japan2009HDAntibody262/539 (49%)0.26 (0.19-0.35)S 3
C 0
O 2
Chang et al[21]South Korea2010HDUrease test and histology12/33 (36%)0.30 (0.12-0.74)S 3
C 0
O 2
Hooman et al[29]Iran2011HD - childrenHistology19/68 (28%)1.59 (0.65-3.92)S 3
C 0
O 2
Genç et al[24]Turkey2013HD and PD - childrenAntibody17/33 (52%)0.69 (0.26-1.83)S 3
C 1
O 2
Chang et al[20]Taiwan2014ESRDUrease test and histology81/144 (56%)0.54 (0.38-0.77)S 4
C 2
O 3
Table 2 Main characteristics of the cohort studies included in this meta-analysis
StudyLo et al[48]Lin et al[14]
CountryHong KongTaiwan
Study designCohort studyCohort study
Year20042015
Study sampleType 2 diabetic patients with clinical proteinuria and renal insufficiencyH. pylori-infected and non-infected patients without ESRD
H. pylori testingAntibodyDiagnosis of H. pylori infection (ICD-9 041.86) was used from inpatient database of The Taiwan National Health Insurance Research Database
Positive H. pylori (Titer > 1.1 U/mL)
ESRD definitionDoubling of baseline serum creatinine concentration or need for dialysis or serum creatinine ≥ 500 μmol/LESRD was identified from Registry for Catastrophic Illness Patient Database
Adjusted HR0.12 (0.03, 0.52)2.58 (2.33, 2.86)
Confounder adjustmentSex, H. pylori status, serum creatinine, hemoglobin, systolic blood pressure, ACE inhibitors, Hepatitis B surface antigen statusAge, sex, comorbidity
Quality assessment (Newcastle-Ottawa scale)Selection: 3Selection: 4
Comparability: 2Comparability: 2
Outcome: 3Outcome: 3